The purpose of this Radioactive Drug Research Committee (RDRC) study is to collect initial
data regarding biodistribution, reproducibility, and dosimetry for the radiotracer Ga-68
PSMA-HBED-CC, an agent which may be useful for the early detection of metastatic prostate
cancer. Investigators will use a test and re-test design in all patients to determine
reproducibility of lesion detection and signal intensity, and will include dynamic imaging in
some patients for the purposes of dosimetry. Patients with known metastatic prostate cancer
will be recruited and imaged on two occasions within the course of 15 days.